{
    "clinical_study": {
        "@rank": "110944", 
        "arm_group": [
            {
                "arm_group_label": "ALXN1101", 
                "arm_group_type": "Experimental", 
                "description": "Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose.  Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose.  Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV."
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 1 single dose study of ALXN1101 in healthy volunteers."
        }, 
        "brief_title": "Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Molybdenum Cofactor Deficiency (MoCD)", 
            "Rare Autosomal Recessive Disorder", 
            "Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)"
        ], 
        "condition_browse": {
            "mesh_term": "Metal Metabolism, Inborn Errors"
        }, 
        "detailed_description": {
            "textblock": "This is a first-in-human (FIH), randomized, blinded, placebo-controlled, single-dose,\n      sequential-cohort, dose-escalation study to evaluate the safety, tolerability, and\n      pharmacokinetics (PK) of a single dose of ALXN1101 in healthy adult subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Male or female subjects \u2265 18 and \u2264 60 years of age and weight \u2265 55 kg and \u2264 100 kg\n\n          2. Willing and able to give written informed consent\n\n          3. Female subjects of child bearing potential must have a negative serum pregnancy test\n             or must be practicing an approved contraceptive regimen for the duration of the study\n\n          4. Male subjects must be practicing an acceptable barrier method of contraception\n\n        Key Exclusion Criteria:\n\n          1. Pregnant or nursing female subjects\n\n          2. QTcF > 450 msec for males and > 470 msec for females, or a family history of Long QT\n             Syndrome.\n\n          3. CrCl < 80 mL/min\n\n          4. CBC in acceptable range;  SGOT or SGPT above the ULN\n\n          5. HIV,  Hepatitis B or Hepatitis C virus infection\n\n          6. Other active systemic infection or malignancy\n\n          7. Investigational drug study within 60 days\n\n          8. Major surgery within the prior 90 days\n\n          9. History of illicit drug use or chronic alcohol dependence within 2 years prior to\n             this study\n\n         10. Positive urine drug toxicology screen or serum alcohol test\n\n         11. Alcohol consumption within 48 hours prior to study drug administration\n\n         12. Recently donated or lost \u2265 499 mL of blood\n\n         13. Recent hormone replacement therapy or use of prescription medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894165", 
            "org_study_id": "ALXN1101-MCD-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALXN1101", 
                "description": "Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.", 
                "intervention_name": "ALXN1101", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "molybdenum cofactor deficiency (MoCD)", 
            "deficiency of activity of molybdenum-dependent enzymes"
        ], 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21225"
                }, 
                "name": "Parexel Baltimore EPCU"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ALXN1101 in Healthy Adult Subjects", 
        "other_outcome": {
            "description": "To evaluate urine, serum or plasma concentrations of biochemical markers including S-sulfocysteine, xanthine, uric acid, creatinine, and other exploratory biochemical markers.", 
            "measure": "Exploratory biochemical marker assessments", 
            "safety_issue": "No", 
            "time_frame": "following the Day 30 visit for the last study subject"
        }, 
        "overall_official": {
            "affiliation": "Parexel Baltimore Early Phase Clinical Unit", 
            "last_name": "Ronald Goldwater, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Physical examination, vital signs, ECGs, laboratory evaluations, and Adverse Events.", 
            "measure": "Safety and tolerability of single dose of ALXN1101 in healthy adult subjects", 
            "safety_issue": "Yes", 
            "time_frame": "following the Day 30 visit for the last study subject"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894165"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "PK parameters of ALXN1101 will be estimated including, but not limited to,maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (tmax), terminal elimination halflife (t\u00bd), area under the plasma concentration-time curve (AUC), total body clearance (CL), and volume of distribution (Vd).", 
            "measure": "PK parameters of ALXN1101", 
            "safety_issue": "No", 
            "time_frame": "following the Day 5 visit for the last study subject"
        }, 
        "source": "Alexion Pharma International Sarl", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexion Pharma International Sarl", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}